Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

OssDsign: First patient enrolment of TOP FUSION

2021-09-08

15:42

OB

Oscar Bergman

Redeye endorses OssDsign's advancement in its clinical study for Catalyst (TOP FUSION), as the first of 17 patients has been enrolled. We still expect first sales to be generated in the US for said product this year but emphasize that adding clinical data supports its chances of a more successful and broader commercialization in the longer term.

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers